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Live-attenuated vaccination with simian immunodeficiency virus (SIV) SIVmac239nef is the most success-
ful vaccine product tested to date in macaques. However, the mechanisms that explain the efficacy of this
vaccine remain largely unknown. We utilized an ex vivo viral suppression assay to assess the quality of the
immune response in SIVmac239nef-immunized animals. Using major histocompatibility complex-matched
Mauritian cynomolgus macaques, we did not detect SIV-specific functional immune responses in the blood by
gamma interferon (IFN-) enzyme-linked immunospot assay at select time points; however, we found that lung
CD8 T cells, unlike blood CD8 T cells, effectively suppress virus replication by up to 80%. These results
suggest that SIVmac239nef may be an effective vaccine because it elicits functional immunity at mucosal sites.
Moreover, these results underscore the limitations of relying on immunological measurements from peripheral
blood lymphocytes in studies of protective immunity to HIV/SIV.
Despite over 25 years of intensive research, efforts to de-
velop a successful prophylactic HIV vaccine have failed (6, 39).
The extraordinary difficulty of developing an HIV vaccine un-
derscores the fact that the elements comprising an effective
immune response directed against HIV are poorly understood.
Simian immunodeficiency virus (SIV) infection of Mauritian
cynomolgus macaques (MCM) provides the best model for
unraveling the correlates of protection against SIV. With SIV
infection of MCM, we can select the timing, route, dose, and
sequence of the infecting virus. Additionally, the limited ge-
netic diversity of MCM facilitates selection of genetically
matched individuals that can be monitored throughout the
acute phase of infection and enables more frequent and inva-
sive sampling, especially of mucosal sites.
Macaques infected with live-attenuated SIV, like
SIVmac239nef, exhibit robust protection from pathogenic
SIV infection (8, 10, 20, 25, 29, 35, 40, 44, 49, 53). While
previous studies have included considerable heterogeneity in
the strain of attenuated SIV, challenge strain, and macaque
species used, they demonstrate collectively the broad spectrum
of attenuated SIVs that effectively protect macaques against
pathogenic challenge. Several studies have also shown that
attenuated SIV effectively protects cynomolgus macaques
against pathogenic challenge using an SIVmac239C8 virus (1–
3). Like SIVmac239nef, this virus has a deletion in the nef
gene, but this deletion is a considerably smaller 12-bp deletion
than the 182-bp deletion in SIVmac239nef (24). Importantly,
there are no studies that establish the protective efficacy of
SIVmac239nef in MCM. Nevertheless, peak SIVmac239nef
viral loads in MCM parallel the range established in rhesus
macaques, between 3.2 103 and 9.4 105 (35), but fall below
peak loads established in a separate study (8). The differences
observed between the rhesus macaque study and our own
could be due to differences in challenge dose. Long-term con-
trol of SIVmac239nef in MCM is also similar to that in rhesus
macaques (35). It is critical to understand why live-attenuated
SIV vaccines are so effective, with the ultimate goal of using
these principals to develop a vaccine that is safe for use in
humans.
There are several plausible explanations for why live-atten-
uated SIV vaccines provide effective protection against chal-
lenge with pathogenic SIV. These explanations range from
viral interference to a robust vaccine-elicited immune response
(19, 43, 45, 47). We currently understand several aspects of
live-attenuated vaccination with SIVmac239nef. First, there
is an inverse relationship between the degree of attenuation
and the level of protection (21). This relationship suggests that
vigorous viral replication is important for the generation of an
effective anti-SIV immune response. Second, the greater the
sequence diversity between the vaccine strain and the chal-
lenge strain, the weaker is the protection provided by the
vaccine (53). This demonstrates that an adaptive immune re-
sponse that recognizes similar epitopes or virus features be-
tween the vaccine and challenge strains is necessary for pro-
tection in this model. Finally, vaccination with live-attenuated
SIV requires a 15- to 20-week induction phase to achieve
protection in the majority of animals (8). Thus, there is a direct
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relationship between the time postvaccination and the degree
of protection between 0 and 20 weeks postvaccination. This
temporal relationship suggests that a fully developed memory
response is required to protect against pathogenic SIV chal-
lenge. Together, these observations argue that SIV-specific
CD8 T-lymphocyte responses might be important in protec-
tion as these responses would be less useful in the setting of
heterologous virus challenge and require both robust viral rep-
lication and time to develop. Such responses, however, can be
weak to nonexistent in the blood of vaccinated animals and
frequently do not correlate with disease progression, leading
some investigators to question their importance in protective
immunity (25, 29, 45, 46). We hypothesize that continued rep-
lication of live-attenuated SIV in the mucosal tissues may lead
to effective, compartmentalized memory T-cell responses that
are important in controlling pathogenic SIV challenge.
It is possible that prophylactic mucosal immunity is required
to prevent viral replication soon after SIV infection and to
minimize the destruction of mucosal immune cells that occurs
within the first 3 weeks of SIV infection (9, 22, 26, 30). Initial
depletion of effector memory CD4 T cells in the gut-associ-
ated lymphoid tissue (GALT) combined with continuous viral
replication leads to prolonged immune activation, eventual
depletion of central memory CD4 T cells, and the develop-
ment of AIDS. An effective mucosal immune response elicited
by live-attenuated SIV vaccination may prevent the initial
CD4 T-cell depletion from the gut. Several recent studies
confirm a critical protective role for CD8 T cells in the genital
tract after vaccination with SHIV89.6, demonstrating that a
mucosal immune response is capable of protecting against or
ameliorating SIV infection (14–16, 48). Another study has also
demonstrated the presence of high-frequency, polyfunctional
T-cell responses in the mucosal tissues of elite controllers, i.e.,
individuals who maintain plasma viral loads below 75 copies/
ml, compared to blood from the same individual, tissues of
noncontrollers, and antiretroviral drug-treated patients. This
study also provides a correlation between mucosal CD8 T-
cell responses and HIV control (12).
While studying gut mucosal tissues is clearly an important
part of understanding HIV/SIV pathology, there are several
challenges to this undertaking. First, accessing gut tissues re-
quires invasive sampling procedures, which are primarily lim-
ited to biopsy or time-of-death studies. Biopsies are often lim-
ited in number throughout the life span of an animal, while
routine necropsy is cost-prohibitive for macaque studies. Sec-
ond, these tissues are nonsterile. The digestive tract is teeming
with floras that contaminate experiments requiring long-term
cell culture. Finally, biopsies of mucosal tissues yield very few
cells. These low cell numbers make ex vivo experiments very
difficult or impossible to perform. Investigators have developed
techniques to assess gut mucosal lymphocyte function by ex-
panding these cells in vitro under sterile conditions with anti-
biotics and then using them in enzyme-linked immunospot
assays (ELISPOT) or intracellular cytokine secretion (ICS)
assays (18, 42). However, these experiments still suffer from
two problems: (i) cells are altered in vitro, which may change
their functional capacity; and, (ii) these experiments still rely
on indirect measures of CD8 T-cell function. These difficul-
ties have limited research on mucosal CD8 T-cell immunity
during SIV infection.
In light of these challenges, we decided to focus on the lung
mucosal tissue, using CD8 T cells isolated from bronchoal-
veolar lavage fluid (BAL). BAL samples lung mucosa where
there are a large number of resident lymphocytes that encoun-
ter respiratory pathogens. Furthermore, BAL provides a min-
imally invasive sampling of a mucosal tissue that can be per-
formed frequently, and BAL harbors effector T cells similar to
GALT (32). These factors make the lung an ideal site for
sampling mucosal CD8 T cells.
We modified an ex vivo viral suppression assay that tests the
ability of CD8 T cells to prevent viral replication in MCM (7,
27, 28, 36, 51, 54, 55). Using this approach, we compared the
suppressive capacity of CD8 T cells isolated from lung and
blood, and we found that CD8 T cells from the lung are more
effective at suppressing viral replication than CD8 T cells
from the blood. This assay does not manipulate lung lympho-
cytes in vitro and provides a direct measure of CD8 T-cell
function. Furthermore, our data support the idea that CD8 T
cells in blood and mucosal tissue are not functionally equiva-
lent, that blood lymphocytes are not a perfect surrogate for
mucosal lymphocytes, and that mucosal T cells attenuate SIV
replication to a greater extent than blood T cells.
MATERIALS AND METHODS
Animal care and infections. Animals were cared for by the Wisconsin National
Primate Research Center (WNPRC) according to protocols approved by the
University of Wisconsin Research Animal Resources Center. All animals were
infected with either molecularly cloned 50,000 50% tissue culture infective doses
(TCID50) of SIVmac239 Nef-open virus intrarectally (23) or 10 ng of p27
SIVmac239nef intravenously (10), kindly provided by Ronald Desrosiers. Sev-
eral SIVmac239-infected animals were infected as part of adoptive transfer
experiments.
Microsatellite analysis of MCM. Animals were haplotyped using our previ-
ously described panel of microsatellite markers spanning the major histocom-
patibility complex (MHC) region (52). These haplotypes were used to infer the
MHC genotypes of the animals for purchasing MHC-matched animals.
Cell preparations. Blood was drawn from animals into EDTA tubes at the
WNPRC and layered over Ficoll-Paque Plus (GE Healthcare Bioscience, Upp-
sala, Sweden); peripheral blood mononuclear cells (PBMC) were isolated by
density centrifugation. BAL was collected by primate center staff. Briefly, saline
solution was flushed into the bronchus and aspirated until fluid was no longer
recovered. BAL was filtered over a 70-m-pore-size cell strainer and then spun
FIG. 1. Vaccination with SIVmac239nef. Animals were infected
intravenously with 10 ng of p27 SIVmac239nef. Virus was measured
in the plasma of vaccinated animals three times a week for the first 4
weeks and every 2 weeks thereafter until week 20. Vaccinated animals
are in color and plotted against wild-type SIVmac239-infected animals
represented by dashed black lines. All animals in the figure are MHC-I
matched. Animal cy0153 was infected as part of an adoptive transfer
experiment.
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and resuspended in complete medium. Effector CD8 T cells were isolated using
an anti-CD8ß-phycoerythrin (PE) monoclonal antibody (Beckman Coulter, Ful-
lerton, CA) and anti-PE beads with LS columns (Miltenyi, Auburn, CA). Targets
were prepared by depleting CD8 cells using the nonhuman primate CD8
cell-positive selection kit from Miltenyi.
CD8-depleted target cells were incubated in T-25 flasks at 37°C for 1 day at
1.5  106 cells/ml with concanavalin A at 5 g/ml. Cells were washed after 24 h
and placed in a new flask in the same volume. After 4 days, cells were washed and
plated at roughly 2  106/ml in 48-well plates.
Virus was prepared by layering 1 ml of 9 109 TCID50 of SIVmac239 over 100
l of 20% sucrose and spinning at 14,000 rpm for 60 min. The supernatant was
removed, and virus was resuspended in complete medium. Twenty-five l of
magnetic beads was added to the resuspended virus, and 30 l of the virus-bead
mix was added to each well of CD8-depleted cells. Plates were placed in the
incubator for 20 min on a magnet to ensure sufficient infection of cells.
CD8 T-cell viral suppression assay (VSA). Infected targets were plated in
96-well plates at 25,000 cells/well. Effectors were plated according to the appro-
priate effector/target (E/T) ratio. After 4 days in culture, cells were initially
surface stained with anti-CD8-Pacific Blue, anti-CD4-allophycocyanin (APC),
and anti-CD3-Alexa Fluor 700 (BD Biosciences, San Jose, CA) and then stained
for intracellular Gag-p27. Anti-Gag p27 antibody 55-2F12 (NIH AIDS Research
and Reference Reagent Program) conjugated to fluorescein isothiocyanate
(FITC) was combined with bulk permeabilization reagent (Invitrogen, Carlsbad,
CA), and cells were incubated at room temperature for 15 min before being
washed and fixed with 2.0% paraformaldehyde. Plates were then run on an
LSRII flow cytometer (BD) using a high-throughput system and analyzed with
FlowJo software, version 8.8.6 (TreeStar, Ashland, OR). All values were nor-
malized by dividing the average percentage of p27-positive (p27) cells in each
well by the average percentage of p27 cells in the control wells with no effectors.
Assays performed using vaccinated animals utilized different but MHC-
matched animals for effectors and targets. In assays testing effector cells from
SIVmac239-infected animals, all VSAs used an autologous system. Six of the
naïve animal assays were performed in an allogeneic MHC-matched system, and
three were autologous.
Tetramer analysis. Peptide-major histocompatibility complex class I tetramer
analysis was performed as previously described (4). Briefly, either freshly isolated
PBMC and BAL or thawed PBMC were stained with Gag386–394-GW9/Mafa-
A1*063, QP8/Mafa-A4*0101, and HL9/Mafa-B*5101 conjugated to either PE or
APC. Cells were incubated at 37°C in complete medium for 1 h and then surface
stained with anti-CD4-peridinin chlorophyll protein (PerCP), anti-CD8-Pacific
Blue, and anti-CD3 Alexa Fluor 700. Cells were subsequently washed twice and
fixed for analysis by flow cytometry using an LSRII instrument (BD). We tested
each vaccinated animal at two separate time points in the PBMC and two
vaccinated animals at a single time point in the BAL.
FIG. 2. Viral suppression assay schematic. (A) Lymphocytes were separated from the blood using Ficoll density centrifugation, and CD8 T
cells were magnetically separated from the lymphocyte preparation. The CD8-depleted cells were then activated with concanavalin A to create
targets. (B) The target cells were combined with SIVmac239 using a previously described magnetofection system. Effector cells were obtained by
magnetically enriching for CD8ß cells. The targets and effectors were then combined in a 96-well plate, which was stained after 4 days for Gag-p27
and other surface markers.
TABLE 1. IFN- ELISPOT analysis of T-cell responses in the
blood postvaccinationa
Peptideb
T-cell response (no. of SFU/1  106 cells) in the indicated
animal at:
3 wks postvaccination 8 wks postvaccination
CY0205 CY0206 CY0213c CY0205 CY0206 CY0213
ConA 3,881 3,826 ND 4,080 9,991 1,094
Pol 241-291 ND 98.3
Vif 41-91 83 ND
Env 841-879 83.3 ND
Env 321-371 153.3 ND
Rev 40-90 118 ND
Gag 361-411 208 ND
Pol 641-691 199.2 ND
Pol 681-727 104.2 ND 103.3
Pol 757-807 98.3
a Three animals were vaccinated with SIVmac239nef, and T-cell responses
were measured using an IFN- ELISPOT assay and stimulation with peptides
spanning the entire viral proteome. Positive responses are reported for pools of
10 overlapping 15-mer peptides. Concanavalin A (ConA) was used as a positive
control.
b Residues are given for the indicated peptide. ConA, concanavalin A.
c Sufficient blood was not available from animal CY0213 to perform ELISPOT
analysis 3 weeks after vaccination. ND, not done.
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IFN- ELISPOT assays. PBMC were isolated by Ficoll-Hypaque gradient
centrifugation. A total of 1 105 cells were incubated in duplicate overnight with
pools of overlapping 15-mer peptides spanning the entire SIV proteome in
gamma interferon (IFN-) ELISPOT plates (Mabtech, Columbus, OH). Me-
dium alone was used as a negative control; concanavalin A was used as a positive
control. Plates were developed according to the manufacturer’s instructions.
Spots were imaged and counted objectively with an ELISPOT reader (AID,
Strasberg, Germany). The mean number of spot-forming units (SFU) in back-
ground wells (medium alone) was subtracted from the mean of the experimental
wells. Responses were considered positive if the mean of the sample and back-
ground wells differed by more than two standard deviations.
Plasma virus analysis. Plasma virus concentration was determined using pre-
viously described methods (52). Briefly, viral RNA was reverse transcribed and
then quantified using a SuperScript III Platinum One-Step Quantitative RT-
PCR System (Invitrogen, Carlsbad, CA) on a LightCycler 2.0 (Roche, Indianap-
olis, IN). The final reaction mixtures (20 l) contained 0.2 mM deoxynucleoside
triphosphates, 3 mM MgSO4, 0.015% bovine serum albumin, 150 ng of random
hexamers (Promega, Madison, WI), 0.8 l of SuperScript III reverse transcrip-
tase and Platinum Taq DNA polymerase in a single enzyme mix, 600 nM am-
plification primers (5-GTCTGCGTCATCTGGTGCATTC-3 and 5-CACTAG
CTGTCTCTGCACTATGTGTTTTG-3), and 100 nM probe (5-6FAM-
CTTCCTCAGTGTGTTTCACTTTCTCTTCTGCG-BHQ1-3, where 6FAM is
6-carboxyfluorescein and BHQ1 is Black Hole Quencher 1). The reverse trans-
criptase reaction was performed at 37°C for 15 min and then at 50°C for 30 min.
An activation temperature of 95°C for 2 min was followed by 50 amplification
cycles of 95°C for 2 min and 62°C for 1 min, with ramp times set to 3° per s. Serial
dilutions of an SIV Gag in vitro transcript were used to generate a standard curve
for each run. Copy numbers were determined by interpolation onto the standard
curve with the LightCycler software, version 4.0.
Statistics. Parametric t tests were performed using GraphPad Prism, version
5.0a for Macintosh (GraphPad Software, San Diego, CA [www.graphpad.com]).
Paired t tests were used for analyses comparing measurements within animals,
and unpaired t tests were used for comparisons of measurements between dif-
ferent animals. Error bars on graphs represent the standard error of the mean.
RESULTS
Live-attenuated vaccination does not induce high-frequency
functional T-cell responses in the blood. We vaccinated three
MHC-matched Mauritian cynomolgus macaques with
SIVmac239nef. Plasma viral loads of SIVmac239nef peaked
between 1  104 and 1  105 copies of viral RNA (vRNA)/ml of
plasma and were controlled to undetectable levels within 4 to 8
weeks in two of three animals (Fig. 1). Animal CY0213 had a
higher acute-phase viral load that remained detectable until 20
weeks postvaccination. In Fig. 1, the dashed lines in black repre-
sent animals infected with wild-type SIVmac239. All animals in
the figure are MHC class I (MHC-I) matched, demonstrating that
SIVmac230nef infection is acutely attenuated in the MCM.
To explore the mechanisms responsible for controlling
SIVmac239nef replication, we performed a full SIV pro-
teome IFN- ELISPOT assay using peptide pools of 15-mers
overlapping by 11 amino acids. However, high-frequency SIV-
specific T-cell responses were not detected in the blood (Table
1). Animals mounted three to four responses by 3 weeks post-
vaccination. Only one animal, CY0206, mounted a response
against a single pool that was detected at both 3 and 8 weeks
postvaccination. Although the three macaques were MHC
matched, we did not detect responses against the same peptide
pools by IFN- ELISPOT assay. The low reproducibility and
lack of high-frequency immune responses in the blood of our
vaccinated animals are consistent with recently published data
using rhesus macaques in which often transient T-cell re-
FIG. 3. CD8 T cells from BAL suppress viral replication at several E/T ratios. (A) The gating strategy used throughout the analysis to
determine the number of p27 target cells is shown. Cells were first gated for lymphocytes based on their light scatter properties; then CD8 cells
were selected. The p27 cells were then quantified as a percentage of the target cells. FFS, forward scatter; SSC, side scatter. (B) Data from a
representative assay are shown. The percentages of p27 cells gated as drawn on the right of each dot plot are shown at each E/T ratio.
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sponses were of similarly low frequency in the vaccine phase 1
month prior to challenge (35) and also concur with a second
study using a different attenuated SIV in the rhesus macaque
model (29). The low-level replication of SIVmac239nef may
ultimately preclude the generation of high-frequency periph-
eral immune responses. It is also possible that transient re-
sponses were mounted between the time points studied but
were not detected due to our sampling interval. In this light, we
next explored whether we could detect functional lymphocytes
at other anatomic sites using avant-garde techniques.
Development and application of a novel viral suppression
assay. To compare CD8 T-cell responses in blood and an
easily accessible mucosal tissue, we elected to sample CD8 T
cells from the lung. Resident lung lymphocytes were obtained
using BAL by flushing the lungs with saline. We repeatedly
recovered approximately 10-fold fewer lymphocytes from BAL
than from blood during our lymphocyte isolations. The low cell
recovery in BAL precludes widespread peptide-specific evalu-
ations of CD8 T-cell activity and is minimally sufficient for
very focused ELISPOT, intracellular cytokine secretion, or
tetramer analyses, which typically use 100,000 to 500,000 cells
per test. Therefore, we examined the functional capacity of
CD8 lymphocytes isolated from these tissues. Specifically, we
modified an ex vivo viral suppression assay that requires only
150,000 CD8 effector cells (Fig. 2).
The gating strategy used to identify SIV-infected cells on the
basis of intracellular Gag p27 levels is shown in Fig. 3A. We
first gated lymphocytes based on forward and side scatter char-
acteristics and then selected CD8-depleted cells to assess the
percentage of targets that were p27. We tested four to six E/T
ratios for the ability of CD8 T cells from both PBMC and
BAL to suppress viral replication (Fig. 3B). The representative
data shown in Fig. 3B display an example of the inverse rela-
tionship between the number of CD8 effector cells in BAL
and the percentage of p27 cells.
CD8 T cells from lung suppress viral replication rapidly
after live-attenuated vaccination. BAL CD8 T cells in the
SIVmac239nef-vaccinated macaques rapidly suppressed
viral replication (Fig. 4) in contrast to CD8 T cells from
PBMC. We observed suppression by 8 days postvaccination
in animal CY0206 (Fig. 4A), at 3 weeks postvaccination in
animal CY0205 (Fig. 4B), and at 3 weeks postvaccination in
animal CY0213 (Fig. 4C). BAL CD8 T cells suppressed
viral replication by up to 80% compared to only 0 to 10% for
the corresponding cells in PBMC. The response in the BAL
and PBMC of animal CY0205, the only animal that was
sampled weekly, remained consistent at time points after 4
weeks postvaccination (Fig. 5).
At the 1:1 and 1:2 E/T ratios, we found that PBMC CD8 T
cells did not suppress viral replication either before or after
vaccination (Fig. 6). In stark contrast, BAL CD8 T cells
suppressed viral replication postvaccination at both the 1:1 E/T
(P  0.0071) and 1:2 E/T (P  0.0047) ratios at the time of
greatest suppression. Furthermore, BAL CD8 T cells post-
vaccination suppressed viral replication to a greater extent
than BAL CD8 T cells prevaccination at both the 1:1 E/T (P
 0.016) and 1:2 E/T (P  0.028) ratios. Baseline VSAs were
performed prevaccination because target and effector cells
were from different, albeit MHC-matched, animals. We did not
observe any background viral suppression due to potential
differences in minor antigens although we noted that PBMC
effector cells in animal CY0213 appeared to stimulate infection
in the baseline assay (Fig. 4). PBMC in this animal did suppress
viral replication compared to baseline levels but did not suppress
viral replication compared to control wells within the same assay.
These results suggest that SIVmac239nef may be generating a
localized immune response at a mucosal site. Importantly, these
results demonstrate that immune responses that are absent or
undetectable in blood may be detectable in other tissues.
Differences in the antiviral efficacy of mucosal and blood
CD8 T cells from SIVmac239-infected cynomolgus ma-
caques. We looked retrospectively at viral suppression in wild-
type SIVmac239-infected MCM. These macaques represented
a heterogenous population of MCM with various immunogenic
backgrounds, plasma viral loads, and durations of infection.
We observed minimal to modest suppression of viral replica-
tion by PBMC and BAL CD8 T cells from uninfected ani-
mals. However, in SIV-infected animals, BAL CD8 T cells
FIG. 4. CD8 T cells from SIVmac239nef-vaccinated animals
suppress viral replication early after infection. CD8 T cells isolated
from BAL and PBMC in SIVmac239nef-vaccinated macaques were
compared in viral suppression assays both before and after vaccination.
All values were normalized by dividing the average percentage of p27
cells in each well by the percentage of p27 cells in the control wells
with no effectors. (A) Eight days postvaccination in animal CY0206.
(B) Three weeks postvaccination in animal CY0205. (C) Three weeks
postvaccination in animal CY0213.
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suppressed viral replication far more efficiently than PMBC
CD8 T cells (Fig. 7). Moreover, we found that this difference
was preserved in E/T ratios as low as 1:4, below which very few
effector cells are present (data now shown).
At the 1:1 and 1:2 E/T ratios, BAL CD8 T cells from
SIV-infected animals exhibited the most potent suppression of
viral replication (Fig. 7A and B). BAL CD8 T cells from
infected animals suppressed viral replication significantly bet-
ter than BAL CD8 T cells from uninfected animals at both
E/T ratios (P 	 0.0001); they also exhibited more potent sup-
pression than PBMC CD8 T cells from infected animals at
both E/T ratios (P  0.002). Of note, BAL CD8 T cells from
uninfected animals also had a weak tendency to suppress viral
replication compared to the corresponding PBMC CD8 T
cells at both the 1:1 E/T (P  0.005) and 1:2 E/T (P  0.025)
ratios. This weak suppression could result from the naturally
activated phenotype of CD8 T cells isolated from extralym-
phoid tissues, where effector memory cells predominate. These
cells are likely already primed against other pathogens and
may be responding and secreting cytokines in response to other
antigens present in the lung, thereby leading to non-SIV-spe-
cific suppression. Finally, PBMC CD8 T cells from infected
animals suppressed more effectively than PBMC CD8 T cells
from uninfected animals at both the 1:1 E/T ratio (P  0.0003)
and 1:2 E/T ratio (P  0.004); this suggests that SIV-suppres-
sive CD8 T cells are systemic after wild-type SIVmac239
infection. The animals were sampled at different time points
postchallenge, thereby making it difficult to assess the relation-
ship between viral suppression and viral loads. However, based
on viral loads taken at the time of the viral suppression assay,
there did not appear to be any correlation between viral load
and viral suppression in PBMC or BAL (data not shown).
Phenotype and specificity of CD8 T cells from PBMC and
BAL. At the completion of the 4-day assay, there were gener-
ally fewer CD8 T cells in wells with BAL effectors than in
wells with PBMC effectors (Fig. 7C). These differences may be
due to the activated phenotype of CD8 T cells isolated from
mucosal tissues, which typically harbor short-lived effector T
cells that may not survive for long periods in culture. We
assessed the percentage of CD8 T effector memory cells in
both the BAL and PBMC at the time point of greatest sup-
pression in each vaccinated animal. Very few central memory
T cells, defined on the basis of CD28 expression within
the CD3 CD8 CD95 T-cell population, were present in the
lung. However, it is unclear whether this would explain the
observed differences in suppression (Fig. 8). It may be that
the lung lymphocytes are less robust and that the process of
isolation and enrichment leads to increased cell death. Also,
the in vitro tissue culture microenvironment might be suffi-
ciently different from that in the lung to compromise the ex-
pansion of BAL CD8 T cells in comparison to CD8 T cells
derived from PBMC. Furthermore, PBMC CD8 T cells could
expand more vigorously in vitro due to the greater central
memory component, which is associated with an increased
proliferative capacity. Overall, however, these differences em-
phasize the ability of lung CD8 T cells to suppress viral
replication. Thus, despite the lower numbers of CD8 T cells
present in the BAL wells, these cells still exhibited a very
strong antiviral effect.
FIG. 5. Consistent suppression of viral replication by BAL-derived
CD8 T cells. Viral suppression by CD8 T cells from BAL and
PBMC was measured weekly for animal CY0205. The graph shows
measurements of p27 cells at the 1:1 E/T ratio; all values were
normalized by dividing the average percentage of p27 cells in the
experimental wells by the percentage of p27 cells in the control wells
with no effectors.
FIG. 6. CD8 T cells isolated from the lung suppress viral replication postvaccination. Measurements represent the time of greatest suppres-
sion from the three vaccinated animals postvaccination. These postvaccination time points were 8 days for CY0206, 4 weeks for CY0205, and 3
weeks for CY0213. Significant P values are indicated above the horizontal lines. E/T ratios are shown above the panels. All values were normalized
by dividing the average percentage of p27 cells in experimental wells by the percentage of p27 cells in the control wells with no effectors.
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Finally, we performed tetramer analysis of PBMC and BAL
samples from vaccinated animals to assess the physical fre-
quency of SIV-specific responses in both tissues. We tested
acute and early chronic-phase PBMC samples with three tet-
ramers (data not shown). Extremely modest cognate CD8
T-cell populations were observed with nearly background lev-
els, as expected in a control, uninfected animal. A single high-
frequency response, specific for the Gag386–394-GW9/Mafa-
A1*063 epitope, was detected in animal CY0213 (Fig. 9).
Notably, the frequency of CD8 T cells detected with the
Gag386–394-GW9/Mafa-A1*063 tetramer in BAL was almost
6.5-fold higher than in PBMC at the same time point (Fig. 9).
Thus, despite the modest responses, these results indicate that
the increased suppression by BAL CD8 T cells may be due to
a higher frequency of SIV-specific T cells in the mucosal tissues
after SIVmac239nef vaccination.
DISCUSSION
An understanding of the correlates of protection in HIV/
SIV infection remains elusive. By comprehending the elements
of an effective immune response against the virus, it may be
possible to develop technologies that engender these same
responses in vaccinated individuals. Here, we modified an ex
vivo viral suppression assay that directly tests the ability of
CD8 T cells to suppress SIV replication. These assays are
similar to those described previously (7, 27, 28, 54, 55) and to
assays reported recently for the investigation of Gag-specific
CD8 T cells in HIV controllers (37). However, in this study,
we tested the ability of CD8 T cells derived from both blood
and lung to suppress viral replication.
We found that cells isolated from the blood of macaques
vaccinated with live-attenuated SIV were not effective at sup-
pressing viral replication. While other investigators have re-
ported vigorous CD8 T-cell responses in the blood of
SIVmac239nef-vaccinated macaques, recent studies have
demonstrated that indirect measurements of CD8 T-cell
function may not represent whether a cell is truly functional (7,
51). The weak responses we detected by IFN- ELISPOT assays
in the blood correlate well with the lack of viral suppression that
we observed. Furthermore, we also measured very low frequen-
cies of SIV-specific responses in the blood by tetramer analysis.
Additional studies have also reported the use of viral suppression
assays to demonstrate the importance of CD8 T-cell function
after vaccination with SIVmac239nef, SIVmac2393, and
simian-human immunodeficiency virus (SHIV) in rhesus ma-
caques (13, 50) and SIVmac251 challenge in cynomolgus ma-
caques (11). In contrast to our experiments, these assays re-
ported viral suppression after vaccination by PBMC CD8 T
cells. These differences could potentially be explained by the
use of higher E/T ratios, different readouts between assays,
differences in the duration of the assay, and, most importantly,
the presence of CD8 natural killer cells. Ultimately, using a
combination of approaches, we measured very few high-fre-
quency CD8 T-cell responses in the blood of vaccinated ma-
caques and were unable to measure viral suppression by these
cells.
We found that CD8 T cells isolated from the lung of
vaccinated macaques were extremely effective at suppressing
viral replication by 8 to 28 days postvaccination. This BAL
CD8 T cell-mediated suppression was maintained at nearly
all time points tested postvaccination; in parallel, we were
never able to detect strong suppression by PBMC CD8 T
cells from the same animals. In contrast to our vaccine
results, we found that CD8 T cells isolated from animals
that were infected with SIVmac239 could suppress viral
FIG. 7. CD8 T cells from BAL suppress viral replication to a
greater extent than CD8 T cells from PBMC. (A and B) Several
infected and uninfected animals were used to assess viral suppression
at different E/T ratios, as indicated above the panels. Significant P
values are indicated above the horizontal lines. All values were nor-
malized by dividing the average percentage of p27 cells in experi-
mental wells by the percentage of p27 cells in the control wells with
no effectors. (C) The percentage of lymphocytes that were CD8 T
cells was measured in the wells at the end of the assay. Higher fre-
quencies of CD8 T cells were present in PBMC samples at the end of
the assay.
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replication regardless of tissue type. However, BAL CD8 T
cells were more effective at suppressing viral replication
than CD8 T cells isolated from the PBMC of the same
animals. Despite the increased suppression by BAL, the
lung is depleted of effector CD4 T cells during SIV infec-
tion, and animals that progress rapidly to AIDS face severe
depletion of BAL CD4 T cells (32, 33). Thus, while it is
likely due to a variety of different factors, it remains unclear
what leads to the development of these effective CD8 T
cells in the lung.
Recent studies have demonstrated an increased level of SIV-
specific T cells present in BAL after vaccination with an SIV
protein-encoding vector based on the rhesus cytomegalovirus
(17). Thus, the previously reported T-cell effector memory
localization in extralymphoid tissues such as BAL may explain
the increased suppression of SIV replication by BAL CD8 T
cells (34). However, in our studies, the disparity in viral sup-
pression between BAL and PBMC did not appear to stem from
consistent differences in the distribution of CD8 T-cell effec-
tor memory populations between PBMC and BAL as defined
by CD28 and CD95 expression. Indeed, while the populations
did appear different between the two sites, they did not display
consistent patterns that might explain the differences in virus
suppression.
Several studies have also addressed the differences between
CD8 T-cell responses in blood and mucosal tissues. A study
using in vitro expanded CD8 T cells from the mucosa and
PBMC in chronically HIV-infected individuals showed similar-
ity in the specificity and magnitude of CD8 T-cell responses
in both tissues (18). Several other studies have also used dif-
ferent methods to show that responses are generally similar
between gut and mucosal tissues including T-cell receptor se-
quencing and tetramer staining (31, 38, 41). These findings
suggest that the differences in the levels of viral suppression
between the two tissues may be related to the quality of the
response and not cell frequency. In agreement with this idea, it
FIG. 8. CD8 T cell effector memory populations from lung and blood. Cells from animals CY0206, CY0205, and CY0213 were stained with
anti-CD28-APC and anti-CD95-PerCP-Cy5.5 to define memory status. Gating is based on lymphocytes and CD8 T cells. The percentage of
effector memory CD8 CD28 CD95 cells is shown in each case.
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was recently reported that there are higher frequencies and
greater functionality of HIV-specific cells in BAL than in blood
(5). We also measured SIV-specific responses at higher fre-
quencies in BAL than blood by tetramer analysis. Although
this response was detected at a very low frequency and al-
though two other CD8 T-cell responses were undetectable by
tetramer analysis, the higher frequency of SIV-specific CD8
T cells in BAL may help explain the effective viral suppression
mediated by BAL CD8 T cells that we consistently observed.
While it would be expected that we detect the BAL tetramer-
positive cells by ELISPOT assay in PBMC at low levels, we did
not observe positive IFN- ELISPOT assay responses using
pools of 15-mers overlapping this region. It is possible that
these responses were missed because pools of 15-mers are not
as sensitive as using the minimal optimal peptide. Additionally,
it is plausible that the tetramer-positive cells we detected either
are not secreting IFN- or are secreting other cytokines that
we did not study. Ultimately, the lack of detectable responses
in the PBMC matches well with the lack of responses detected
by tetramer analysis in the PBMC. SIVmac239nef may rep-
licate primarily in the mucosal tissues, generating responses
that are at very low frequency and difficult to detect in the
PBMC. Importantly, these results demonstrate that measure-
ments of immunity in blood during vaccination may be under-
estimating the magnitude of the elicited immune response.
The early detection of CD8 T-cell responses in the lung
initially seems incongruent with previous reports that protec-
tion requires a 15- to 20-week induction phase. However, it is
entirely possible that these early responses need to develop
into a long-lived memory response to be effective after wild-
type SIVmac239 challenge. It may also be the case that con-
tinued replication and adaptation of SIVmac239nef with the
immune response leads to CD8 T-cell responses against both
the infecting strain and potential escape mutations. This co-
evolution of host immunity and virus may help to explain the
effectiveness of SIVmac239nef and the reason for the lengthy
induction phase. Nevertheless, the ability of mucosal CD8 T
cells to suppress viral replication early after vaccination con-
trasts with the long induction phase required for protection
against pathogenic challenge. Still, the generation of immune
responses in the lung is concurrent with the rapid decline of
SIVmac239nef plasma loads. This early suppression may help
to explain the rapid and better control of acute-phase
SIVmac239nef plasma loads, which are consistently lower than
acute-phase wild-type SIVmac239 plasma loads (data not shown).
Ultimately, these results further cement the differences in
FIG. 9. Gag386–394-GW9/Mafa-A1*063 tetramer analysis of PBMC and BAL from uninfected animal CY0207 and animal CY0213 at 8 weeks
postvaccination. Plots depict the percentages of CD3 CD4 CD8 tetramer-positive cells. The Gag386–394-GW9/Mafa-A1*063 tetramer was the
only one of three that detected a positive response above background. GW9 APC, Gag386–394-GW9/Mafa-A1*063 conjugated to APC.
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immune responses that exist in different anatomical compart-
ments of an HIV/SIV-infected individual. Future work must
assess the ability of this assay to define in vivo disease outcome.
While researchers frequently rely on easily accessible blood
draws to obtain immune readouts, this tissue is not a perfect
proxy for accurate assessments of the immune response against
the virus, and the lung may not be the perfect proxy for GALT.
The present study demonstrates that CD8 T cells from mu-
cosal tissues are more efficient at preventing viral replication ex
vivo and provides a unique method for assessing the suppres-
sive capacity of such cells in macaques either infected with or
vaccinated against SIV.
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